Rescheduling Won't Let Troops Use Marijuana, Military Warns

Photo by Mick Latter via Pexels.

Marijuana's federal status has moved more in the last five months than it did in the previous five decades. Trump's December 2025 executive order set the machinery in motion, and by April 2026 the DEA had actually pulled FDA-approved and state-licensed medical marijuana products out of Schedule I and dropped them into Schedule III. For patients, state-licensed operators, and anyone watching the rescheduling fight from the outside, that's a genuinely big deal.

Inside the ranks, none of it matters. The Pentagon and the Army have said as much in plain language: nothing about a service member's legal exposure for using marijuana has changed, and nothing in the pipeline suggests it will. That's not an oversight or a lag in updating the paperwork -- it's a deliberate, structural gap between how fast civilian and state marijuana law is moving and how frozen military law remains. Understanding why requires looking at what actually changed in April, what's still being litigated, and why the Uniform Code of Military Justice was never really part of the conversation to begin with.

What Actually Changed: From Executive Order to Scheduling Action

Photo by KATRIN BOLOVTSOVA via Pexels.

The chain of events starts with an executive order Trump signed on December 18, 2025, directing the Attorney General to move "expeditiously" on relocating marijuana from Schedule I to Schedule III of the Controlled Substances Act. That's a significant instruction on its own, but executive orders don't rewrite scheduling by themselves -- someone at DOJ has to actually do the administrative work. That happened on April 23, 2026, when Acting Attorney General Todd Blanche and the DEA announced a Rescheduling Order placing FDA-approved and state-licensed medical marijuana products into Schedule III, effective immediately.

That same announcement did double duty. It didn't just reschedule a defined subset of products -- it also kicked off an expedited administrative hearing process to address broader rescheduling questions that the narrower order didn't resolve. That hearing ran from June 29 through no later than July 15, 2026, presided over by Chief Administrative Law Judge Derek C. Julius.

None of this happened in a vacuum. As Ohio State University's Drug Enforcement and Policy Center has pointed out, this hearing is really a continuation of a process that traces back to a proposed rulemaking from May 2024, under the Biden administration. That earlier hearing process got pulled and restarted after Blanche withdrew it, meaning the current track represents round two of an effort that's now spanned two administrations. The upshot: the legal architecture around marijuana rescheduling is still being built in real time, with the April order representing a concrete step forward but not necessarily the final word on how broadly rescheduling will apply.

Legal Challenges Still Pending in Court

Photo by Matthew Jackson via Pexels.

Rescheduling on paper doesn't mean rescheduling free of legal challenge. On May 22, 2026, Nebraska, Indiana, and Louisiana filed a joint petition for review of the Rescheduling Order in the U.S. Court of Appeals for the D.C. Circuit -- the standard venue for challenges to federal agency action of this kind. That petition doesn't stand alone; it joins an earlier lawsuit brought by Smart Approaches to Marijuana, an anti-legalization advocacy group that's been a persistent litigant against federal cannabis policy shifts for years.

What this means practically is that the rescheduling framework, even though it's already been implemented and is already affecting how FDA-approved and state-licensed medical products are classified, isn't settled law. Courts could narrow it, remand pieces of it back to DEA, or in theory unwind parts of the order entirely. States and companies that have already begun operating on the assumption that Schedule III status is locked in are, in a legal sense, building on ground that could still shift.

For the medical marijuana industry and for patients relying on state-licensed products, the D.C. Circuit litigation is the thing to actually watch over the next year -- more so, arguably, than the DEA's own administrative hearing process. A ruling that upholds the order cements the current framework. A ruling that finds fault with how DOJ and DEA got there could send the whole question back to square one, or at minimum delay further movement on rescheduling beyond the narrow category of products currently covered.

Article 112a and the Military's Zero-Tolerance Line

Photo by Gustavo Fring via Pexels.

None of the civilian-side movement touches Article 112a of the Uniform Code of Military Justice, which bans use, possession, distribution, and manufacture of marijuana by service members outright, regardless of what schedule it sits on or what any individual state allows. Article 112a doesn't reference the Controlled Substances Act's scheduling tiers in a way that would make Schedule III status a defense -- it's a standalone military justice provision, and it stays exactly as strict as it was before April 2026.

The Army has reinforced this at the regulatory level too. Army Regulation 600-85 prohibits all cannabis and cannabinoid products for soldiers, and that includes CBD -- a product category most civilians think of as legally uncomplicated. The Army's Directorate of Prevention, Resilience and Readiness has publicly warned that even CBD products "can pose serious risks to Soldiers and mission readiness," largely because of contamination and mislabeling issues that can cause a service member to fail a drug test despite believing they were using a THC-free product.

A DOJ spokesman addressed the disconnect directly, noting that rescheduling would likely not affect military members any differently than civilians in terms of the federal illegality question, since marijuana remains a federally controlled substance even under Schedule III -- it's simply regulated differently than a Schedule I drug, not decriminalized. American Legion National Commander Dan Wiley put it about as plainly as it can be put: "Reclassification is not legalization and does not mandate use." That's the sentence every service member should internalize before assuming rescheduling changes anything about what they can put in their body while in uniform.

Recruiting Rules Are Loosening Even As Use Stays Banned

Photo by JOSE GALLARDO via Pexels.

There's a separate track of change happening in recruiting policy that's easy to confuse with a loosening on use -- it isn't. A March 2026 update to Army enlistment regulations means that a single marijuana possession conviction on an applicant's record no longer automatically requires a waiver to enlist. For recruiters trying to hit accession targets, that's a meaningful shift, since past low-level marijuana charges have long been one of the more common disqualifying factors screened out early in the process.

That change didn't happen in isolation. The Continuing Appropriations and Extensions Act of 2026 pushed the Department of Defense toward what's being called a "Waiver-First" model for recruits with certain disqualifying histories, essentially flipping the default so that more applicants get considered rather than automatically excluded pending a waiver review. This standardizes, across all branches, an approach the Navy piloted back in 2024 under what it internally called its "Waiver Revolution" -- an effort to widen the recruiting pool without changing conduct standards once someone is actually in uniform.

The distinction here matters enormously and is exactly where confusion tends to creep in. Easier entry standards for people with a past marijuana conviction is a recruiting and accessions policy question, aimed at expanding the pool of eligible applicants in a competitive recruiting environment. It has nothing to do with tolerance for use once someone raises their right hand and enlists. A recruit who benefits from the waiver-free enlistment pathway is still bound by Article 112a and AR 600-85 from day one of service, with zero carryover of leniency from the recruiting stage into active duty conduct standards.

Veterans Still Locked Out of VA Cannabis Recommendations

Photo by National Cancer Institute via Unsplash.

Veterans face their own version of this gap, and it's arguably more frustrating because it involves medical care rather than discipline. Federal law still prohibits the Department of Veterans Affairs from prescribing or even formally recommending marijuana as a treatment option, regardless of how many states have legalized medical or recreational use and regardless of the Schedule III shift for FDA-approved and state-licensed products.

There was a real chance to change this recently. Legislation that would have allowed VA doctors to at least discuss and potentially recommend cannabis as part of a treatment plan got stripped from the bill that ended the government shutdown -- a familiar pattern where cannabis provisions get traded away in last-minute negotiations over must-pass legislation.

The practical result is a veteran living in a state with a fully legal medical or recreational program can walk into a state-licensed dispensary, but can't get their VA physician to officially discuss cannabis as a treatment option, write anything resembling a recommendation, or coordinate it as part of an overall care plan. That leaves veterans managing conditions like chronic pain or PTSD navigating two separate and disconnected systems -- their state's legal market and their federal health care provider -- with no bridge between them. As rescheduling proceeds elsewhere in the federal system, this particular restriction on VA care hasn't moved, and there's no indication it's next in line to change.

Strip away the headlines and the rescheduling story happening right now is almost entirely a civilian and state-market story. It's reshaping how FDA-approved and state-licensed medical products get classified, it's generating real litigation in the D.C. Circuit, and it's forcing DEA through another round of administrative hearings. None of that has touched the UCMJ, and nothing currently sitting in Congress or working its way through the courts looks likely to change that anytime soon.

For anyone currently serving or planning to enlist, the safe assumption is that federal military law applies in full regardless of what your home state allows or what the FDA has approved. Article 112a and AR 600-85 don't care about Schedule III status, state legalization, or even CBD's reputation as the harmless cousin of THC. Before making any assumptions based on what you've read about rescheduling, confirm current standards directly with your branch -- policies on waivers and enlistment have been moving, and it's easy to conflate that movement with a change in conduct standards that simply hasn't happened.

The D.C. Circuit challenges from Nebraska, Indiana, Louisiana, and Smart Approaches to Marijuana are worth watching if you care about where civilian rescheduling ultimately lands, as is the outcome of DEA's broader hearing process under Judge Julius. Those could genuinely reshape the civilian and state-market picture over the next year or two. But troops and veterans should plan around a different reality: Article 112a has outlasted decades of state-level legalization already, and there's no serious reason to expect this round of federal rescheduling to be the thing that finally reaches it.